PARP1 and plasma cell myeloma: In multiple myeloma models, Caracciolo et al. [81] demonstrated the effectiveness of PARPi olaparib in the treatment of MYC-proficient cells, with a similar pattern of DNA-damage and cell death seen after PARP1 knockout, suggesting a synthetic lethality model correlating the axis MYC-PARP1.